Overview

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease

Status:
Completed
Trial end date:
2020-11-12
Target enrollment:
Participant gender:
Summary
This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of ORY-2001 in mild to moderate Alzheimer's Disease patients.
Phase:
Phase 2
Details
Lead Sponsor:
Oryzon Genomics S.A.
Collaborators:
Alzheimer's Drug Discovery Foundation
Alzheimer’s Drug Discovery Foundation